Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

onartuzumab

- PMLiVE

Scientists recommend new imaging technique to support design of innovative cancer drugs

Cryo-EM helped to determine the detailed structures of CAK, a promising target for cancer drugs

- PMLiVE

New study reveals discrepancies in FDA accelerated approval process for cancer drugs

The study looked at 46 different cancer drugs that received accelerated approvals between 2013 and 2017

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours

The ADC has been authorised to treat adults with unresectable or metastatic HER2-positive tumours

- PMLiVE

Merck KGaA and Caris enter oncology partnership worth over $1.4bn

The alliance is aimed at accelerating the development of ADCs for cancer patients

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi in small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer cases

- PMLiVE

UK universities awarded over £58m by Cancer Research UK for clinician scientist training

The funding builds on the charity’s previous Clinical Academic Training Programme Award investment in 2019

- PMLiVE

Genmab to expand oncology portfolio through $1.8bn ProfoundBio acquisition

The deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours

- PMLiVE

Scientists to develop vaccine to prevent lung cancer following £1.7m grant

Lung cancer is responsible for over 48,000 cases in the UK every year

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

Gilead gains rights to Xilio’s early-stage solid tumour candidate in deal worth up to $647.5m

XTX301 is currently being evaluated in a phase 1 trial in patients with advanced solid tumours

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

ICR study shows how dormant breast cancer cells can be targeted to prevent relapse

Oestrogen receptor positive breast cancer accounts for up to 80% of all breast cancers cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links